Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00679042 · ClinicalTrials.gov registry record · Phase 3
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
A Phase 3 study of Type 1 Diabetes Mellitus, sponsored by CellTrans.
- Active
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00679042 is a Phase 3 study of Type 1 Diabetes Mellitus that is active but no longer recruiting, run by CellTrans. The registered enrollment target is 21 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00679042, a Phase 3 study of Type 1 Diabetes Mellitus, is active but no longer recruiting, sponsored by CellTrans.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the present Phase 3 clinical trial is to demonstrate the safety and efficacy of allogeneic islet transplantation in improving glycemic control in Type 1 diabetic patients using the UIC protocol that was developed and proven effective during the Phase 1/2 clinical trial.
Conditions Studied
Interventions
- BIOLOGICAL Islets of Langerhans transplantation
Study Locations (1)
Illinois
- University of Illinois at Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2007-09-05 |
| Est. Completion | 2026-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00679042
The ClinicalTrials.gov registry entry for NCT00679042 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (85% lower). The listed sponsor is CellTrans, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Islets of Langerhans transplantation is the first listed.
NCT00679042 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00679042 about?
NCT00679042 is a clinical study titled "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol". In an earlier Phase 1/2 clinical trial using the Edmonton Protocol of steroid free immunosuppression, investigators at University of Illinois at Chicago (UIC) demonstrated the safety of islet preparation, iset transplantation, and medical treatment at UIC. Therefore, the primary purpose of the prese...
What is the current status of trial NCT00679042?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2007-09-05. Estimated completion is 2026-06-14.
What conditions does trial NCT00679042 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00679042?
The interventions under investigation include: Islets of Langerhans transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00679042?
This trial is sponsored by CellTrans, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00679042 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
RECRUITING · Phase 3
-
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
COMPLETED · Phase 3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Pediatric Diabetics Type 1 Using InsuPatch
COMPLETED · Phase 3
-
Efficacy of Islet After Kidney Transplantation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.